

RECEIVED  
CENTRAL FAX CENTER

OCT 30 2007

**FAX TRANSMISSION**

DATE: October 30, 2007

PTO IDENTIFIER: Application Number 10/510,876  
Patent Number

Inventor: Power et al.

MESSAGE TO: USPTO PTAS System

FAX NUMBER: (571) 273-8300

FROM: ROPES &amp; GRAY LLP

Jesse A. Fecker, Ph.D.

PHONE: (617) 951-7633

Attorney Dkt. #: SLII-P01-001

PAGES (Including Cover Sheet): 3

CONTENTS: Supplemental Information Disclosure Statement (2 pages)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 951-7633 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

ROPES &amp; GRAY LLP

One International Place, Boston, Massachusetts 02110-2624

Telephone: (617) 951-7000 Facsimile: (617) 951-7050

RECEIVED  
CENTRAL FAX CENTER

OCT 30 2007

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: October 30, 2007

Signature: Pamela Harrison  
(Pamela Harrison)Docket No.: SLII-P01-001  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Power et al.

Application No.: 10/510,876

Confirmation No.: 6247

Filed: June 20, 2005

Art Unit: 1647

For: USE OF OSTEOPROTEGERIN FOR THE  
TREATMENT AND/OR PREVENTION OF  
FIBROTIC DISEASE

Examiner: R. M. Deberry

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Applicants wish to draw the Examiner's attention to the following Office Actions which have been issued in association with related, co-pending applications:

1. Office Action dated February 20, 2007 in association with USSN 10/966,845.

Applicants encourage the Examiner to contact them if a copy of the Office Action is required.

This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of

10735013\_1.DOC

Application No.: 10/510,876


Docket No.: SLII-P01-001

this Supplemental Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. SLII-P01-001.

Dated: October 30, 2007

Respectfully submitted,

By   
Jesse A. Fecker, Ph.D.  
Registration No.: 52,883  
ROPES & GRAY LLP  
One International Place  
Boston, Massachusetts 02110  
(617) 951-7000  
(617) 951-7050 (Fax)  
Attorneys/Agents For Applicant